News
The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback